Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | ALK fusion |
Gene Variant Detail | |
Relevant Treatment Approaches | ALK Inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05015010 | Phase II | Alectinib | Alectinib in Neo-adjuvant Treatment of Stage III NSCLC (ALNEO) | Recruiting | ITA | 0 |
NCT03334617 | Phase II | AZD9150 + Durvalumab Durvalumab + Olaparib Cediranib + Durvalumab Durvalumab + Vistusertib Durvalumab + Trastuzumab deruxtecan Ceralasertib + Durvalumab | Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON) | Recruiting | USA | FRA | ESP | DEU | CAN | AUT | 2 |
NCT04513925 | Phase III | Atezolizumab + Tiragolumab Durvalumab | A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (SKYSCRAPER-03) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 19 |
NCT05014815 | Phase II | BGBA1217 + Tislelizumab Tislelizumab | Ociperlimab With Tislelizumab and Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer | Recruiting | USA | 3 |
NCT02134886 | Phase I | Erlotinib | Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection | Terminated | USA | 0 |
NCT04923126 | Phase Ib/II | PD-0325901 | SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma | Recruiting | USA | 0 |
NCT02154490 | Phase II | Docetaxel Nivolumab Palbociclib Durvalumab Ipilimumab + Nivolumab AZD4547 Taselisib Durvalumab + Tremelimumab Erlotinib + Rilotumumab Talazoparib Erlotinib | Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer | Completed | USA | CAN | 0 |
NCT03164616 | Phase III | Durvalumab + Tremelimumab Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Cisplatin + Gemcitabine Carboplatin + Gemcitabine Durvalumab Carboplatin + Nab-paclitaxel | Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). | Recruiting | USA | DEU | 17 |
NCT03391869 | Phase III | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT03166631 | Phase I | BI 754091 + BI 891065 BI 891065 | A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread | Terminated | USA | 0 |
NCT04612751 | Phase I | Datopotamab Deruxtecan + Durvalumab | Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab With or Without Carboplatin in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung04) | Recruiting | USA | FRA | 1 |
NCT04656652 | Phase III | Docetaxel Datopotamab Deruxtecan | Study of DS-1062A Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-LUNG01) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 18 |
NCT04892953 | Phase II | Carboplatin + Durvalumab + Paclitaxel Carboplatin + Durvalumab + Nab-paclitaxel Carboplatin + Durvalumab + Gemcitabine Durvalumab | Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy | Not yet recruiting | USA | 0 |
NCT03970746 | Phase Ib/II | PDC*lung01 + Pembrolizumab PDC*lung01 + Pemetrexed Disodium PDC*lung01 | Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC | Recruiting | FRA | DEU | BEL | 2 |
NCT04268550 | Phase II | Selpercatinib | Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial) | Recruiting | USA | 0 |
NCT05153408 | Phase Ib/II | BLU-701 BLU-701 + Osimertinib BLU-701 + Carboplatin + Pemetrexed Disodium | (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC | Recruiting | USA | 0 |
NCT04267237 | Phase II | Atezolizumab + RO7198457 Atezolizumab | A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer | Withdrawn | 0 | |
NCT04581824 | Phase II | Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Dostarlimab-gxly + Pemetrexed Disodium Carboplatin + Dostarlimab-gxly + Pemetrexed Disodium | Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | 7 |
NCT04591431 | Phase II | Everolimus Nivolumab Itacitinib Erlotinib Ponatinib Pemigatinib Ipatasertib Ipilimumab Cobimetinib Atezolizumab Palbociclib Entrectinib Vemurafenib Lapatinib Trastuzumab Brigatinib Alectinib Ado-trastuzumab emtansine Pertuzumab Vismodegib | The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (ROME) | Recruiting | ITA | 0 |
NCT03993873 | Phase Ib/II | TPX-0022 | Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET | Recruiting | USA | FRA | ESP | 1 |
NCT02314481 | Phase II | Vemurafenib Atezolizumab Alectinib Ado-trastuzumab emtansine | Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (DARWINII) | Recruiting | 1 | |
NCT04094610 | Phase Ib/II | Repotrectinib | A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations | Recruiting | USA | CAN | 4 |
NCT04940637 | Phase II | Dostarlimab-gxly + Niraparib | UNITO-001-A Phase II Study in HRR/PDL1 Positive MPM/NSCLC | Recruiting | ITA | 0 |
NCT03965468 | Phase II | Carboplatin + Durvalumab + Paclitaxel | Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC (CHESS) | Recruiting | ESP | 2 |
NCT04512430 | Phase II | Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed Disodium | Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients | Recruiting | ESP | 0 |
NCT03255083 | Phase I | DS-1205c + Osimertinib | DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer | Terminated | 1 | |
NCT03639714 | Phase Ib/II | GRT-C901 + GRT-R902 + Ipilimumab + Nivolumab | A Study of a Personalized Neoantigen Cancer Vaccine | Active, not recruiting | USA | 1 |
NCT04108026 | Phase II | Durvalumab | Immunotherapy in Patient With Poor General Condition (SAVIMMUNE) | Recruiting | FRA | 0 |
NCT04471428 | Phase III | Docetaxel Atezolizumab + Cabozantinib | Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy (CONTACT-01) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | BEL | AUT | 8 |
NCT03904108 | Phase II | Ramucirumab | Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy | Terminated | USA | 0 |
NCT04776447 | Phase II | Atezolizumab + Carboplatin + Paclitaxel | Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) | Recruiting | ESP | 0 |
NCT03155620 | Phase II | Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | Recruiting | USA | 1 |
NCT04467801 | Phase II | Ipatasertib Docetaxel + Ipatasertib | Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy | Recruiting | USA | 0 |
NCT05006794 | Phase I | GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies | Recruiting | USA | 0 |
NCT04644237 | Phase II | Trastuzumab deruxtecan | Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (DESTINY-LUNG02) | Active, not recruiting | USA | ITA | FRA | ESP | CAN | 5 |
NCT04856176 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab + Sargramostim Carboplatin + Paclitaxel + Pembrolizumab + Pemetrexed Disodium + Sargramostim | A Study of Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advanced Non-small Cell Lung Cancer | Recruiting | USA | 0 |
NCT04589845 | Phase II | Alectinib Ado-trastuzumab emtansine Ipatasertib GDC-0077 Entrectinib Atezolizumab Idasanutlin | Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 16 |
NCT02949843 | Phase II | Nivolumab + Pembrolizumab | Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations | Terminated | USA | 0 |
NCT03999710 | Phase II | Durvalumab | Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT02693535 | Phase II | Cobimetinib + Vemurafenib Atezolizumab + Talazoparib Regorafenib Larotrectinib Trastuzumab + Tucatinib Ipilimumab + Nivolumab Palbociclib Afatinib Entrectinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab/trastuzumab/hyaluronidase-zzxf Crizotinib Abemaciclib Sunitinib Olaparib | TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR) | Recruiting | USA | 0 |
NCT02657434 | Phase III | Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Atezolizumab + Carboplatin + Pemetrexed Disodium Atezolizumab + Cisplatin + Pemetrexed Disodium | A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132) | Active, not recruiting | USA | ITA | FRA | ESP | BEL | AUT | 21 |
NCT04746924 | Phase III | Tislelizumab BGBA1217 + Tislelizumab Pembrolizumab | A Study of BGB-A1217 With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer | Recruiting | USA | ITA | FRA | ESP | DEU | 12 |
NCT04895579 | Phase I | Copanlisib + Durvalumab | Lung Cancer With Copanlisib and Durvalumab (LCD) | Recruiting | USA | 0 |
NCT03915951 | Phase II | Binimetinib + Encorafenib | An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer | Recruiting | USA | ITA | ESP | 2 |
NCT00939770 | Phase Ib/II | Crizotinib | Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma | Completed | USA | CAN | 0 |
NCT03066661 | Expanded access | Entrectinib | Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions | No longer available | USA | 0 |
NCT04116541 | Phase II | Alectinib Cabozantinib Ribociclib + Siremadlin | A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. (MegaMOST) | Recruiting | FRA | 0 |
NCT03191786 | Phase III | Atezolizumab Gemcitabine Vinorelbine | A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naive Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy (IPSOS) | Active, not recruiting | ITA | ESP | DEU | CAN | BEL | 20 |
NCT05171777 | Phase II | Atezolizumab | A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer | Recruiting | USA | ITA | ESP | CAN | 7 |
NCT04655976 | Phase II | Docetaxel Docetaxel + Dostarlimab-gxly + TSR-022 Docetaxel + Dostarlimab-gxly | Study of Cobolimab in Combination With Dostarlimab and Docetaxel in Advanced NSCLC Participants (COSTAR Lung) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | 11 |
NCT05077709 | Phase II | IO102-IO103 + Pembrolizumab | IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC | Recruiting | USA | 1 |
NCT04863248 | Phase II | Docetaxel + Trilaciclib Docetaxel | Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4) | Terminated | USA | 0 |
NCT04541407 | Phase I | Osimertinib + Temozolomide Lorlatinib + Temozolomide | Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease | Active, not recruiting | USA | 0 |
NCT05170204 | Phase III | Durvalumab Alectinib Pralsetinib Entrectinib | A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) | Not yet recruiting | 1 | |
NCT03037385 | Phase Ib/II | Pralsetinib | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | BEL | 7 |
NCT04585815 | Phase Ib/II | Axitinib + PF-06801591 + SGN-TGT Binimetinib + Encorafenib + PF-06801591 | A Study of Sasanlimab With Other Therapies in People With Non-small Cell Lung Cancer | Recruiting | USA | CAN | BEL | 3 |
NCT04995523 | Phase Ib/II | AZD2936 | A Study to Assess the Safety and Efficacy of AZD2936 in Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) (ARTEMIDE-01) | Recruiting | ESP | BEL | 5 |
NCT03755102 | Phase I | Dacomitinib | A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib. | Recruiting | USA | 0 |
NCT03213652 | Phase II | Ensartinib | Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) | Recruiting | USA | 1 |
NCT04294810 | Phase III | Atezolizumab Atezolizumab + Tiragolumab | A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (SKYSCRAPER-01) | Recruiting | USA | ITA | FRA | ESP | DEU | AUT | 19 |
NCT03775486 | Phase II | Durvalumab + Olaparib Cisplatin + Durvalumab + Pemetrexed Disodium Durvalumab Carboplatin + Durvalumab + Gemcitabine Carboplatin + Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Nab-paclitaxel Cisplatin + Durvalumab + Gemcitabine | Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) | Active, not recruiting | USA | BEL | 10 |
NCT04956692 | Phase III | Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab | Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) | Recruiting | USA | FRA | ESP | 11 |
NCT05004116 | Phase Ib/II | Irinotecan + Repotrectinib + Temozolomide | A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer | Recruiting | USA | 0 |
NCT04211337 | Phase III | Vandetanib Cabozantinib Selpercatinib | A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 14 |
NCT04984811 | Phase II | Atezolizumab + NT-I7 | NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC | Recruiting | USA | 0 |
NCT04827576 | Phase II | Docetaxel + Hu5F9-G4 | Study of Magrolimab in Participants With Solid Tumors | Recruiting | USA | 0 |
NCT03107988 | Phase I | Cyclophosphamide + Lorlatinib + Topotecan Lorlatinib | NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) | Recruiting | USA | FRA | CAN | 1 |
NCT05064280 | Phase II | Lenvatinib Pembrolizumab | Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases | Recruiting | USA | 0 |
NCT04862780 | Phase Ib/II | BLU-945 | Study Targeting EGFR Resistance Mechanisms in NSCLC | Recruiting | USA | ESP | 6 |
NCT05061550 | Phase II | Durvalumab + Monalizumab Durvalumab + Oleclumab | Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (NeoCOAST-2) | Recruiting | USA | ITA | FRA | ESP | CAN | 2 |
NCT04929041 | Phase II | Pembrolizumab Nab-paclitaxel Ipilimumab Paclitaxel Nivolumab Pemetrexed Disodium Carboplatin | Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative | Recruiting | USA | 0 |
NCT04725188 | Phase II | Docetaxel Docetaxel + MK-7684A MK-7684A | Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002) | Recruiting | USA | ITA | FRA | ESP | DEU | BEL | AUT | 13 |
NCT04619797 | Phase II | Atezolizumab + Pemetrexed Disodium + Tiragolumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Atezolizumab + Carboplatin + Pemetrexed Disodium + Tiragolumab Atezolizumab + Cisplatin + Pemetrexed Disodium + Tiragolumab | A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 6 |
NCT02097810 | Phase I | Entrectinib | Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations. (STARTRK-1) | Completed | USA | 1 |
NCT04005144 | Phase I | Binimetinib + Brigatinib | Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer | Recruiting | USA | 0 |
NCT04484142 | Phase II | Datopotamab Deruxtecan | Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | 5 |
NCT05048797 | Phase III | Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Trastuzumab deruxtecan | A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 12 |
NCT02587650 | Phase II | Ceritinib Capmatinib Regorafenib Entrectinib | Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma | Terminated | USA | 0 |
NCT05012254 | Phase II | Ipilimumab + Nivolumab Carboplatin + Ipilimumab + Nivolumab + Paclitaxel Cisplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium | Study of Nivolumab and Ipilimumab Plus Chemotherapy as a Treatment for Patients With Stage IV Lung Cancer With Brain Metastases (NIVIPI-Brain) | Recruiting | ESP | 0 |
NCT03827850 | Phase II | Erdafitinib | FGFR Inhibitor in FGFR Dysregulated Cancer (FIND) | Recruiting | DEU | 0 |
NCT04083976 | Phase II | Erdafitinib | A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 9 |
NCT04302025 | Phase II | Cobimetinib + Vemurafenib Entrectinib Atezolizumab Alectinib Pralsetinib | A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT03906071 | Phase III | Docetaxel Nivolumab + Sitravatinib | Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer (SAPPHIRE) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 5 |
NCT04800822 | Phase I | PF-07284892 Cetuximab + Encorafenib + PF-07284892 Lorlatinib + PF-07284892 Binimetinib + PF-07284892 | PF-07284892 in Participants With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04758949 | Phase II | Nivolumab FL-101 + Nivolumab FL-101 | FL-101 in Surgically Resectable Non-Small Cell Lung Cancer | Withdrawn | 0 | |
NCT04832854 | Phase II | Atezolizumab + Carboplatin + Pemetrexed Disodium + Tiragolumab Atezolizumab + Carboplatin + Paclitaxel + Tiragolumab Atezolizumab + Tiragolumab Atezolizumab + Cisplatin + Pemetrexed Disodium + Tiragolumab Atezolizumab + Carboplatin + Gemcitabine + Tiragolumab Atezolizumab + Cisplatin + Gemcitabine + Tiragolumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Carboplatin + Paclitaxel Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium | A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer | Recruiting | USA | ESP | 2 |
NCT05005273 | Phase II | Ipilimumab + Nivolumab BMS-986207 + Ipilimumab + Nivolumab | A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer | Not yet recruiting | USA | ITA | FRA | ESP | DEU | BEL | 7 |
NCT04047862 | Phase I | BGBA1217 + Tislelizumab BGBA1217 + Cisplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Carboplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Carboplatin + Paclitaxel + Tislelizumab BGBA1217 + Carboplatin + Nab-paclitaxel + Tislelizumab BGBA1217 + Cisplatin + Etoposide + Tislelizumab BGBA1217 + Carboplatin + Etoposide + Tislelizumab | Study of BGB-A1217 in Combination With Tislelizumab in Advanced Solid Tumors | Recruiting | USA | 5 |
NCT03057106 | Phase II | Cisplatin Gemcitabine Carboplatin Durvalumab + Tremelimumab Pemetrexed Disodium | Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC | Active, not recruiting | CAN | 1 |
NCT05117242 | Phase II | GEN1046 + Pembrolizumab GEN1046 | Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Another Anti-cancer Therapy for Treatment of Recurrent (Non-small Cell) Lung Cancer | Recruiting | USA | ESP | 1 |
NCT02650401 | Phase I | Entrectinib | Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options (STARTRK-NG) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | 5 |
NCT04644315 | Phase II | Alectinib | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors (ALpha-T) | Recruiting | USA | 0 |
NCT04526782 | Phase II | Docetaxel Binimetinib + Encorafenib | ENCOrafenib With Binimetinib in bRAF NSCLC (ENCO-BRAF) | Recruiting | FRA | 0 |
NCT03563716 | Phase II | Atezolizumab + Tiragolumab Atezolizumab | A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Active, not recruiting | USA | FRA | ESP | 3 |
NCT04774718 | Phase Ib/II | Alectinib | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Patients With ALK Fusion-Positive Solid or CNS Tumors | Recruiting | USA | ITA | FRA | ESP | CAN | 3 |
NCT00932451 | Phase II | Crizotinib | An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene | Completed | USA | ITA | FRA | ESP | DEU | CAN | 16 |
NCT03420508 | Phase II | Ensartinib | Treating Patients With Melanoma and ALK Alterations With Ensartinib | Active, not recruiting | USA | 0 |
NCT03868423 | Phase II | Brigatinib | Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers | Withdrawn | USA | 0 |